DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 21, 2025
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Sale
Common Stock
2025-01-17$29.96/sh−1,235$36,998→ 57,561 total - Award
Common Stock
2025-01-21+28,508→ 86,069 total
Footnotes (2)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2025.
- [F2]This represents a Restricted Stock Unit award granted on January 21, 2025 that vest 25% annually over four years from grant date subject to continued service.